Skip to main content

Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune uses cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment and potentially autoimmune disease.

Dr. Lars Nieba brings more than 25 years of experience in biopharmaceutical leadership in R&D, business and clinical development, venture capital, manufacturing and product strategy and has been CEO and a Scientific Advisor to a number of biotechnology companies. Dr. Nieba has held previous positions in big pharma and VC firms including Roche, Bayer and Pureos Bioventures where he touched a wide variety of modalities in drug development, from small molecules, through to therapeutic proteins, antibodies and gene therapies.

Rodrigo Vazquez-Lombardi, CSO of Engimmune, said: “The entire Engimmune team is very excited to welcome Lars as CEO and looks forward to working together with him to advance our programs closer to clinic. I am confident that his impressive track record in leadership roles across early stage, clinical and commercial development of biotherapeutics will rapidly become an invaluable asset to realise the unique potential of our technology platforms for TCR drug development.”

Read also about how Engimmune Therapeutics is advancing cancer treatment through collaboration.

Share this article

View all news

Sign up to receive our newsletter in your inbox.